Insider Selling: Globus Medical (NYSE:GMED) Director Sells 5,000 Shares of Stock

Globus Medical, Inc. (NYSE:GMED) Director Ann Rhoads sold 5,000 shares of the firm’s stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $85.00, for a total transaction of $425,000.00. Following the completion of the sale, the director directly owned 35,384 shares in the company, valued at approximately $3,007,640. This trade represents a 12.38% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Globus Medical Stock Down 6.9%

Shares of NYSE:GMED traded down $5.97 during midday trading on Thursday, hitting $81.13. 4,075,147 shares of the stock traded hands, compared to its average volume of 1,481,982. The stock has a market capitalization of $10.89 billion, a PE ratio of 20.75, a P/E/G ratio of 1.28 and a beta of 0.98. The business’s 50 day moving average is $77.48 and its two-hundred day moving average is $83.35. Globus Medical, Inc. has a one year low of $60.36 and a one year high of $101.40.

Globus Medical (NYSE:GMED) last posted its earnings results on Thursday, November 5th. The medical device company reported $1.23 earnings per share for the quarter, topping analysts’ consensus estimates of $1.20 by $0.03. The company had revenue of $763.72 million during the quarter, compared to analyst estimates of $792.39 million. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. As a group, sell-side analysts forecast that Globus Medical, Inc. will post 4.99 earnings per share for the current year.

Hedge Funds Weigh In On Globus Medical

Hedge funds have recently bought and sold shares of the company. Washington Trust Advisors Inc. boosted its stake in Globus Medical by 116.8% in the 2nd quarter. Washington Trust Advisors Inc. now owns 45,006 shares of the medical device company’s stock worth $3,556,000 after purchasing an additional 24,250 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Globus Medical during the second quarter valued at approximately $1,858,000. WCM Investment Management LLC bought a new stake in shares of Globus Medical during the first quarter valued at approximately $16,965,000. Public Employees Retirement System of Ohio purchased a new position in shares of Globus Medical in the second quarter worth $7,941,000. Finally, Congress Asset Management Co. lifted its holdings in shares of Globus Medical by 6.6% in the third quarter. Congress Asset Management Co. now owns 361,026 shares of the medical device company’s stock worth $27,041,000 after buying an additional 22,401 shares in the last quarter. Institutional investors own 95.16% of the company’s stock.

Key Globus Medical News

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Third-quarter adjusted earnings were $1.23 per share, above the $1.20 consensus and up from $1.18 a year earlier. The company also increased its share-repurchase authorization by $500 million, which could support shareholder returns. Third-quarter results and repurchase announcement
• Neutral Sentiment: Globus Medical’s acquisition of Synaptive Medical expands its presence in cranial neurosurgery. The strategic opportunity may broaden its technology portfolio, though the supplied reports do not quantify the deal’s expected financial contribution. Synaptive Medical acquisition
• Negative Sentiment: Quarterly revenue of $763.7 million missed analysts’ $792.4 million estimate. The company’s FY 2026 revenue outlook of $3.1 billion also came in below the $3.2 billion consensus, tempering the positive EPS surprise. Full-year EPS guidance of $4.95–$5.05 was broadly in line with the $5.00 consensus. Quarterly results and guidance

Analysts Set New Price Targets

A number of brokerages recently commented on GMED. Zacks Research upgraded Globus Medical from a “hold” rating to a “strong-buy” rating in a report on Monday, August 10th. BMO Capital Markets initiated coverage on Globus Medical in a research report on Wednesday, July 8th. They set an “outperform” rating and a $94.00 price target on the stock. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Globus Medical in a research note on Friday, October 9th. UBS Group started coverage on Globus Medical in a research report on Tuesday, July 28th. They set a “neutral” rating and a $82.00 price objective for the company. Finally, Truist Financial reduced their target price on shares of Globus Medical from $115.00 to $100.00 and set a “buy” rating on the stock in a research report on Thursday, July 16th. Three investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Globus Medical presently has a consensus rating of “Moderate Buy” and an average target price of $99.46.

Globus Medical Company Profile

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.